60
Participants
Start Date
March 12, 2024
Primary Completion Date
June 30, 2027
Study Completion Date
June 30, 2027
AZD0754
"Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce AZD0754.~During AZD0754 production, subjects may receive bridging therapy for disease control. Upon successful generation of AZD0754 product, subjects will receive treatment with AZD0754 therapy.~Study treatment will include lymphodepleting chemotherapy followed by one dose of AZD0754 administered by intravenous (IV) infusion."
RECRUITING
Research Site, East Melbourne
NOT_YET_RECRUITING
Research Site, New York
RECRUITING
Research Site, New York
RECRUITING
Research Site, Philadelphia
RECRUITING
Research Site, Atlanta
RECRUITING
Research Site, Tampa
RECRUITING
Research Site, St Louis
NOT_YET_RECRUITING
Research Site, Westwood
RECRUITING
Research Site, Houston
RECRUITING
Research Site, Duarte
WITHDRAWN
Research Site, Duarte
NOT_YET_RECRUITING
Research Site, Boston
RECRUITING
Research Site, Hackensack
Lead Sponsor
AstraZeneca
INDUSTRY